Oncology Institute Inc. (TOIIW)
Oncology Institute Statistics
Share Statistics
Oncology Institute has 75.56M shares outstanding. The number of shares has increased by null% in one year.
| Shares Outstanding | 75.56M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | - |
| Failed to Deliver (FTD) Shares | - |
| FTD / Avg. Volume | -% |
Short Selling Information
The latest short interest is 0, so 0% of the outstanding shares have been sold short.
| Short Interest | 0 |
| Short % of Shares Out | 0% |
| Short % of Float | 0% |
| Short Ratio (days to cover) | 0 |
Valuation Ratios
The PE ratio is -1.81 and the forward PE ratio is null.
| PE Ratio | -1.81 |
| Forward PE | null |
| PS Ratio | 0.46 |
| Forward PS | null |
| PB Ratio | 2.64 |
| P/FCF Ratio | -3.68 |
| PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Oncology Institute Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.12, with a Debt / Equity ratio of 2.1.
| Current Ratio | 4.12 |
| Quick Ratio | 3.73 |
| Debt / Equity | 2.1 |
| Total Debt / Capitalization | 67.73 |
| Cash Flow / Debt | -0.3 |
| Interest Coverage | -11.36 |
Financial Efficiency
Return on equity (ROE) is -1.46% and return on capital (ROIC) is -43.57%.
| Return on Equity (ROE) | -1.46% |
| Return on Assets (ROA) | -0.4% |
| Return on Capital (ROIC) | -43.57% |
| Revenue Per Employee | 405.30K |
| Profits Per Employee | -103.83K |
| Employee Count | 800 |
| Asset Turnover | 1.55 |
| Inventory Turnover | 19.35 |
Taxes
| Income Tax | -36.00K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is 0.62, so Oncology Institute 's price volatility has been higher than the market average.
| Beta | 0.62 |
| 52-Week Price Change | null% |
| 50-Day Moving Average | 0.01 |
| 200-Day Moving Average | 0.07 |
| Relative Strength Index (RSI) | 63.49 |
| Average Volume (20 Days) | - |
Income Statement
In the last 12 months, Oncology Institute had revenue of 324.24M and earned -83.07M in profits. Earnings per share was -0.92.
| Revenue | 324.24M |
| Gross Profit | 59.57M |
| Operating Income | -77.02M |
| Net Income | -83.07M |
| EBITDA | -70.45M |
| EBIT | -77.02M |
| Earnings Per Share (EPS) | -0.92 |
Balance Sheet
The company has 33.49M in cash and 119.67M in debt, giving a net cash position of -86.19M.
| Cash & Cash Equivalents | 33.49M |
| Total Debt | 119.67M |
| Net Cash | -86.19M |
| Retained Earnings | -146.15M |
| Total Assets | 179.18M |
| Working Capital | 69.67M |
Cash Flow
In the last 12 months, operating cash flow was -36.31M and capital expenditures -4.57M, giving a free cash flow of -40.88M.
| Operating Cash Flow | -36.31M |
| Capital Expenditures | -4.57M |
| Free Cash Flow | -40.88M |
| FCF Per Share | -0.55 |
Margins
Gross margin is 18.37%, with operating and profit margins of -23.75% and -25.62%.
| Gross Margin | 18.37% |
| Operating Margin | -23.75% |
| Pretax Margin | -25.63% |
| Profit Margin | -25.62% |
| EBITDA Margin | -21.73% |
| EBIT Margin | -23.75% |
| FCF Margin | -12.61% |
Dividends & Yields
TOIIW does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
Currently there are no analyst rating for TOIIW.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | -0.19 |
| Piotroski F-Score | 2 |